Literature DB >> 3034030

Ramipril: review of pharmacology.

R A Becker, B Schölkens.   

Abstract

Ramipril is a potent orally active converting enzyme inhibitor. Its active metabolite ramiprilat is classified as a reversible, slow- and tight-binding inhibitor. Ramipril lowers blood pressure in various models of hypertension and improves states of acute cardiac failure mainly by suppression of angiotensin II formation. Actions on both vasoconstrictor and volume factors are involved because ramipril causes vasodilation and mild natriuresis but preserves potassium. Sustained inhibition of converting enzyme in target tissues such as vascular wall, kidney and heart may explain cardiovascular changes over the long term. Ancillary effects may possibly emerge from modulation of the sympathetic nervous system but the contribution of bradykinin potentiation remains unclear.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3034030     DOI: 10.1016/0002-9149(87)90045-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

Review 1.  Newer ACE inhibitors. A look at the future.

Authors:  A Salvetti
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  A physiological role for pressure-dependent renin release in long-term blood pressure control.

Authors:  H Ehmke; P Persson; H Kirchheim
Journal:  Pflugers Arch       Date:  1987-11       Impact factor: 3.657

3.  Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.

Authors:  H Schunkert; J Kindler; M Gassmann; W Lahn; R Irmisch; E Ritz; E R Debusmann; J O Pujadas; K M Koch; H G Sieberth
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 4.  Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Differential systemic and regional hemodynamic profiles of four angiotensin-I converting-enzyme inhibitors in the rat.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

6.  Overexpressed angiotensin-converting enzyme in neutrophils suppresses glomerular damage in crescentic glomerulonephritis.

Authors:  Suguru Saito; Narihito Tatsumoto; Duo-Yao Cao; Nobuyuki Nosaka; Hiroshi Nishi; Daniel N Leal; Ellen Bernstein; Kenichi Shimada; Moshe Arditi; Kenneth E Bernstein; Michifumi Yamashita
Journal:  Am J Physiol Renal Physiol       Date:  2022-08-18

7.  Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).

Authors:  D W Cushman; F L Wang; W C Fung; G J Grover; C M Harvey; R J Scalese; S L Mitch; J M DeForrest
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.